Clinical Study to Evaluate Efficacy of Cabergoline Compared to Coasting in Reducing Ovarian Hyperstimulation Syndrome in Women Undergoing Fertility Treatment

What this Trial Is About

Ovarian hyperstimulation syndrome (OHSS) is a serious complication that can occur during controlled ovarian stimulation in stimulated ovarian cycles. It is believed to result from the release of factors like vascular endothelial growth factor, which increase capillary permeability and cause fluid to leak from blood vessels. This leads to blood thickening and complications such as increased risk of blood clots and reduced blood flow to organs. This clinical trial evaluates the effectiveness of cabergoline compared to coasting in reducing the incidence of OHSS in women undergoing ovarian stimulation. The study involves two groups: one group will receive cabergoline at a dose of 0.25 mg daily for 8 days starting from the day of HCG trigger, while the other group will undergo coasting, which means temporarily stopping human menopausal gonadotropin injections for 1 to 3 days while continuing agonist treatment until estradiol levels drop to a safer level. The coasting group may also receive cabergoline daily for 8 days in some cases. OHSS will be monitored early on the day of embryo transfer and 7 days after, with late OHSS assessed 14 days after embryo transfer. Participants will be closely monitored for OHSS occurrence and severity over one month. Assessments include hormone level measurements and follicle monitoring. The study uses a randomized, double-blind design to compare the treatments. Women aged 18 to 38 with a high risk of OHSS and specific hormone levels are eligible. Safety is monitored throughout, and the study is sponsored by Tanta University with a planned end date in November 2026.

Clinical Study to Evaluate Efficacy of Cabergoline to Coasting in Reducing the Incidence of Ovarian Hyperstimulation Syndrome